Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous dendritic cell vaccine (Edward Ziga)
- Development stage
- Unknown
- Lead developer
- University of Miami
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
This is an autologous dendritic cell vaccine developed by Edward Ziga in collaboration with the HGG Immuno Group for the treatment of pediatric brain tumors. The therapy involves collecting a patient's peripheral blood mononuclear cells (PBMCs) via leukapheresis, which are then differentiated into dendritic cells. These cells are partially matured and administered intradermally at sites pre-treated with topical imiquimod, a Toll-like receptor 7 (TLR7) agonist, to enhance in situ maturation and immune activation. The vaccine is used in conjunction with autologous tumor lysate to provide a broad range of tumor-associated antigens, aiming to induce a robust anti-tumor T-cell response against refractory central nervous system tumors.
- Other names
- DC vaccineDendritic Cell Vaccine with Imiquimod for Pediatric Brain Tumors
Beyond the preview
Go deeper on Autologous dendritic cell vaccine (Edward Ziga).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous dendritic cell vaccine (Edward Ziga).